Unity Biotechnology reports Q1 EPS (34c), consensus (48c)

Cash, cash equivalents and marketable securities totaled $38.3M as of March 31, compared with $43.2M as of December 31, 2023. UNITY believes that current cash, cash equivalents and marketable securities are sufficient to fund operations into the Q3 of 2025. “Our team remains focused on the enrollment and execution of our Phase 2b ASPIRE study in diabetic macular edema, comparing UBX1325 (foselutoclax) against aflibercept,” said Anirvan Ghosh, CEO of UNITY. “We were pleased to not only have been able to upsize our ASPIRE study to 50 patients as previously announced, but we also were able to extend the duration of the study to 36 weeks in order to better assess the durability of UBX1325 compared to aflibercept after final dosing at week 16. Patients and practitioners could benefit greatly from UBX1325 as a potentially new treatment option leveraging a new mechanism of action to help stave off or even reverse the vision loss from diabetic macular edema.”